Trials / Unknown
UnknownNCT03118180
CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma.
Detailed description
A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma. Complete remission rate, overall survival rate, relapse rate and CRS rate were monitored. CART associated toxicities were also monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19 targeted chimeric antigen receptor T cells | CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma |
Timeline
- Start date
- 2017-04-05
- Primary completion
- 2018-12-31
- Completion
- 2020-12-31
- First posted
- 2017-04-18
- Last updated
- 2017-04-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03118180. Inclusion in this directory is not an endorsement.